Your browser doesn't support javascript.
loading
Show: 20 | 50 | 100
Results 1 - 5 de 5
Filter
Add filters








Language
Year range
1.
Journal of Korean Medical Science ; : 943-952, 2015.
Article in English | WPRIM | ID: wpr-210689

ABSTRACT

Traumatic brain injury (TBI) is associated with poor neurological outcome, including necrosis and brain edema. In this study, we investigated whether agmatine treatment reduces edema and apoptotic cell death after TBI. TBI was produced by cold injury to the cerebral primary motor cortex of rats. Agmatine was administered 30 min after injury and once daily until the end of the experiment. Animals were sacrificed for analysis at 1, 2, or 7 days after the injury. Various neurological analyses were performed to investigate disruption of the blood-brain barrier (BBB) and neurological dysfunction after TBI. To examine the extent of brain edema after TBI, the expression of aquaporins (AQPs), phosphorylation of mitogen-activated protein kinases (MAPKs), and nuclear translocation of nuclear factor-kappaB (NF-kappaB) were investigated. Our findings demonstrated that agmatine treatment significantly reduces brain edema after TBI by suppressing the expression of AQP1, 4, and 9. In addition, agmatine treatment significantly reduced apoptotic cell death by suppressing the phosphorylation of MAPKs and by increasing the nuclear translocation of NF-kappaB after TBI. These results suggest that agmatine treatment may have therapeutic potential for brain edema and neural cell death in various central nervous system diseases.


Subject(s)
Animals , Male , Rats , Active Transport, Cell Nucleus/drug effects , Agmatine/therapeutic use , Apoptosis/drug effects , Aquaporins/metabolism , Blood-Brain Barrier/physiopathology , Brain Edema/drug therapy , Brain Injuries/pathology , Mitogen-Activated Protein Kinases/metabolism , Motor Cortex/pathology , NF-kappa B/metabolism , Phosphorylation/drug effects , Rats, Sprague-Dawley
2.
Journal of Korean Medical Science ; : S210-S216, 2014.
Article in English | WPRIM | ID: wpr-191059

ABSTRACT

Wound healing is initiated and progressed by complex integrated process of cellular, physiologic, and biochemical events, such as inflammation, cell migration and proliferation. Interleukin 6 (IL-6) is a multifunctional cytokine, and it could regulate the inflammatory response of wound healing process in a timely manner. Hyaluronic acid (HA) is an essential component of the extracellular matrix, and contributes significantly to cell proliferation and migration. The purpose of this study was to investigate the effects of IL-6 or/and HA on the cell migration process in human keratinocytes. Combining IL-6 and HA significantly increased the cell migration in scratch based wound healing assay. The phosphorylation of extracellular-signal-regulated kinase (ERK) was significantly increased after 1 hr of IL-6 and HA treatment, but the phosphorylation of p38 mitogen-activated protein kinase (MAPK) was not. We also found that significant increase of the NF-kappaB translocation from cytoplasm into nucleus after 1 hr of IL-6 or/and HA treatments. This study firstly showed that synergistic effects of combining IL-6 and HA on the cell migration of wound healing by activation of ERK and NF-kappaB signaling. Further studies might be required to confirm the synergistic effects of HA and IL-6 in the animal model for the development of a novel therapeutic mixture for stimulation of wound healing process.


Subject(s)
Humans , Active Transport, Cell Nucleus/drug effects , Cell Line , Cell Movement/drug effects , Cell Proliferation/drug effects , Cell Survival/drug effects , Enzyme Activation/drug effects , Extracellular Signal-Regulated MAP Kinases/metabolism , Hyaluronic Acid/pharmacology , Interleukin-6/pharmacology , Keratinocytes/metabolism , MAP Kinase Signaling System/drug effects , NF-kappa B/metabolism , Phosphorylation/drug effects , Protein Transport/drug effects , Wound Healing , p38 Mitogen-Activated Protein Kinases/metabolism
3.
Experimental & Molecular Medicine ; : e47-2013.
Article in English | WPRIM | ID: wpr-223715

ABSTRACT

Here, we report that B-cell lymphoma 2 (Bcl-2) is a novel target molecule of aspirin in breast cancer cells. Aspirin influenced the formation of a complex by Bcl-2 and FKBP38 and induced the nuclear translocation of Bcl-2 and its phosphorylation. These events inhibited cancer cell proliferation and subsequently enhanced MCF-7 breast cancer cell apoptosis. Bcl-2 knockdown using small interfering RNA (siRNA) delayed apoptotic cell death, which correlated with increased proliferation following aspirin exposure. In contrast, Bcl-2 overexpression enhanced the onset of aspirin-induced apoptosis, which was also associated with a significant increase in Bcl-2 phosphorylation in the nucleus. Therefore, this study may provide novel insight into the molecular mechanism of aspirin, particularly its anticancer effects in Bcl-2- and estrogen receptor-positive breast cancer cells.


Subject(s)
Humans , Active Transport, Cell Nucleus/drug effects , Apoptosis , Aspirin/pharmacology , Cell Nucleus/metabolism , MCF-7 Cells , Phosphorylation , Protein Binding , Proto-Oncogene Proteins c-bcl-2/genetics , Tacrolimus Binding Proteins/metabolism
4.
Experimental & Molecular Medicine ; : 787-797, 2010.
Article in English | WPRIM | ID: wpr-122637

ABSTRACT

Cholangiocarcinoma (CC) is a chemoresistant intrahepatic bile duct carcinoma with a poor prognosis. The aims of this study were to identify molecular pathways that enhance sesquiterpene lactone parthenolide (PTL)-induced anticancer effects on CC cells. The effects of PTL on apoptosis and hemoxygenase-1 (HO-1) induction were examined in CC cell lines. The enhancement of PTL-mediated apoptosis by modulation of HO-1 expression and the mechanisms involved were also examined in an in vitro cell system. Low PTL concentrations (5 to 10 micrometer) led to Nrf2-dependent HO-1 induction, which attenuated the apoptogenic effect of PTL in Choi-CK and SCK cells. PTL-mediated apoptosis was enhanced by the protein kinase C-alpha inhibitor Ro317549 (Ro) through inhibition of expression and nuclear translocation of Nrf2, resulting in blockage of HO-1 expression. Finally, HO-1 silencing resulted in enhancement of apoptotic cell death in CC cells. The combination of PTL and Ro efficiently improved tumor growth inhibition compared to treatment with either agent alone in an in vivo subcutaneous tumor model. In conclusion, the modulation of HO-1 expression substantially improved the anticancer effect of PTL. The combination of PTL and Ro could prove to be a valuable chemotherapeutic strategy for CC.


Subject(s)
Humans , Active Transport, Cell Nucleus/drug effects , Antineoplastic Agents/chemistry , Apoptosis/drug effects , Cell Line, Tumor , Cell Nucleus/metabolism , Cholangiocarcinoma/drug therapy , Drug Resistance, Neoplasm/drug effects , Enzyme Activation , Enzyme Inhibitors/pharmacology , Heme Oxygenase-1/genetics , Lactones/chemistry , NF-E2-Related Factor 2/genetics , Protein Kinase C-alpha/antagonists & inhibitors , RNA, Small Interfering/genetics , Sesquiterpenes/chemistry , Signal Transduction/drug effects
5.
Experimental & Molecular Medicine ; : 757-764, 2009.
Article in English | WPRIM | ID: wpr-71507

ABSTRACT

Monocyte chemoattractant protein-1 (MCP1) plays a key role in monocyte/macrophage infiltration to the sub-endothelial space of the blood vessel wall, which is a critical initial step in atherosclerosis. In this study, we examined the intracellular signaling pathway of IL-1beta-induced MCP1 expression using various chemical inhibitors. The pretreatment of a phosphatidylcholine (PC)-specific PLC (PC-PLC) inhibitor (D609), PKC inhibitors, or an NF-kappaB inhibitor completely suppressed the IL-1beta-induced MCP1 expression through blocking NF-kappaB translocation to the nucleus. Pretreatment with inhibitors of tyrosine kinase or PLD partially suppressed MCP1 expression and failed to block nuclear NF-kappaB translocation. These results suggest that IL-1beta induces MCP1 expression through activation of NF-kappaB via the PC-PLC/PKC signaling pathway.


Subject(s)
Humans , Active Transport, Cell Nucleus/drug effects , Aorta/pathology , Atherosclerosis/immunology , Bridged-Ring Compounds/pharmacology , Cell Nucleus/metabolism , Cells, Cultured , Chemokine CCL2/biosynthesis , Estrenes/pharmacology , Genistein/pharmacology , Interleukin-1beta/metabolism , Myocytes, Smooth Muscle/drug effects , NF-kappa B/metabolism , Phospholipases/antagonists & inhibitors , Protein-Tyrosine Kinases/antagonists & inhibitors , Pyrrolidinones/pharmacology , Recombinant Proteins/metabolism , Signal Transduction/drug effects , Thiones/pharmacology
SELECTION OF CITATIONS
SEARCH DETAIL